Rubicon Research has entered into a definitive agreement with Neuronasal, Inc., to acquire Common Stock in tranches, for a total consideration of up to $2.5 million. The transaction is a minority investment in Neuronasal Inc. relating to the development of pharmaceutical products.
Rubicon Research is a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets and in particular the United States.
